{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.2","upperLimit":"24.3","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"OS is defined as the number of days from the date of the first dose of study drug to the date of death due to any cause. If a participant was not known to have died, OS was censored at the last known alive date. The distribution of OS was estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG000","title":"Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"}],"paramType":"MEDIAN","populationDescription":"All enrolled Phase 2 participants who received venetoclax; this endpoint was pre-specified for Phase 2 only, data are reported for all participants with available data","reportingStatus":"POSTED","timeFrame":"Estimated median duration of follow-up was 31.7 months","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}